Civi­ca nabs tri­al part­ner as it forges ahead to cre­ate more af­ford­able in­sulins

A non­prof­it drug man­u­fac­tur­er is mov­ing for­ward with plans to stem the ris­ing tide of in­sulin costs in the US.

Utah-based Civi­ca has se­lect­ed Ger­man-based re­search or­ga­ni­za­tion Pro­fil as its hu­man clin­i­cal tri­al part­ner to sup­port the de­vel­op­ment of Civi­ca’s af­ford­able in­sulins. Civi­ca is plan­ning to pro­duce three in­sulin biosim­i­lars – dubbed glargine, lispro and as­part – each of which will be avail­able both in vials and pre-filled pens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER